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     Oltipraz (OPZ), a member of a class of 1,2-dithiolethiones, is known to induce a phase 2 
enzyme response in cells, leading to the induction of various genes with an antioxidant function. 
The phase 2 response plays an important role in the detoxification of electrophilic xenobiotics. 
Due to this property, OPZ can be useful as an anticancer chemopreventive agent and is currently 
used in a phase II clinical trial against Aflatoxin B1-induced hepatocellular carcinoma. Therefore 
it is important to identify and understand the molecular mechanisms through which OPZ initiates 
the phase 2 enzyme responses. 
The induction of the cellular phase 2 response involves oxidative modifications in the Kelch-like 
ECH-associated protein-1 (Keap1) protein, leading to dissociation of its binding partner, the 
nuclear transcription factor erythroid 2p45 (NF-E2)-related factor 2 (Nrf2), which then 
transactivates various antioxidant genes. Given that the mitochondrial electron transport chain 
(ETC) is the major source of cellular reactive oxygen species (ROS) in most cells, the goal of the 
present study was to investigate the role of the ETC in the stimulation of the phase 2 enzyme in 
response to OPZ. To this end, lymphoblastic leukemic CEM cells lacking mitochondrial DNA 
(mtDNA) (ρ0) and hence a functional ETC were generated. These cells were then used to 
determine the effects of OPZ on the phase 2 response and protection of electrophile-induced 
mitochondrial and cellular damage. 
     To investigate effects of OPZ on the phase 2 response, both CEM parental  (ρ+) and ρ0 cells 
were pretreated with OPZ. Levels of reduced glutathione (GSH) (total and mitochondrial) and 





To further investigate whether OPZ-induced phase 2 response is protective against 
diethylmaleate (DEM) induced oxidative stress, both GSH levels and GST activity were 
measured again after pretreatment of both cell lines with OPZ followed by incubation 
with DEM. Flow cytometry analysis was carried out to determine levels of ROS, 
superoxide and mitochondrial membrane potential (Δψm) in these cells. Ultrastructure of 
mitochondria of OPZ pretreated CEM ρ+ cells before and after DEM treatment was 
investigated with Transmission Electron microscopy (TEM). Finally cell viability of both 
OPZ pretreated CEM ρ+ and ρ0 cells was determined after DEM treatment. 
It was found that reduced total and mitochondrial GSH levels and GST activity were 
significantly increased after pretreatment with OPZ in both  ρ+and ρ0 cells and both cell lines 
were resistant to mitochondrial oxidation, loss of Δψm  and cell death in response to the GSH 
depleting agent DEM. 
           These results show that OPZ is an effective inducer of the phase 2 response in CEM cells     
      and confers protection against electrophile-induced oxidative stress, warranting its further    
      investigation as an anticancer chemopreventive. Furthermore, the OPZ-mediated phase 2  
      response and cellular protection was intact in cells lacking mtDNA, suggesting a    
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1.  INTRODUCTION  
 
1.1 Phase 2 enzyme responses 
     Human beings are exposed daily to large amounts of pro-oxidants and electrophiles 
derived from environmental and dietary sources, thus making us more susceptible to 
diseases such as cancer, neurological disorders and cystic fibrosis. Oxidative stress is also 
known to contribute to aging [Townsend et al. 2003].  
1.1.1 Origin of oxidative stress and electrophiles 
A) Oxidative stress 
 
     Oxidative stress is a disturbance in the pro-oxidant-antioxidant balance in favor of the 
former, leading to cellular damage [Sies 1991]. It is either caused by increased 
production of highly reactive oxidizing species such as ROS or reactive nitrogen species 
(RNS) or caused by reduced amount of antioxidants [Halliwell and Gutteridge 1999; 
Winyard et al. 2005]. The highly oxidizing species are either produced to participate in 
the host defence and inflammatory responses or are generated as byproducts of normal 
energy metabolism [Halliwell and Gutteridge 1999]. In most cells, the mitochondrial 
ETC is the main source of ROS during normal cellular respiration. For instance, during 
adenosine triphosphate (ATP) synthesis by the mitochondrial ETC, a significant amount 
of electrons “leak” and combine with molecular oxygen (O2) to form superoxide.  
Mitochondrial respiratory complexes I and III have been identified as the major sites of 
the superoxide production in the mitochondrial ETC. Superoxide is then quickly 
dismutated by the manganese superoxide dismutase (Mn-SOD) to hydrogen peroxide  
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 (H2O2)  [Halliwell and Gutteridge 1999]. H2O2 via the Fenton reaction can give rise to the 
highly reactive hydroxyl radical which damages DNA, proteins and membranes.  
Cells have a number of strategies to protect themselves from ROS-induced damage. For 
instance, antioxidant defense enzymes such as Mn-SOD and copper-zinc superoxide 
dismutase (CuZnSOD) inactivate superoxide, while catalase and glutathione peroxidase 
(GPx) inactivate H2O2.  In addition, there are dietary antioxidants such as vitamin E and 
vitamin C that contribute to protection from ROS-induced damage. 
The antioxidant protective mechanisms in the body are reduced when the dietary intake 
of antioxidant nutrients is insufficient or when the genes for antioxidant defense enzymes 
are mutated [Halliwell and Gutteridge 1999]. Continued or prolonged oxidative stress 
will lead to diseases like Alzheimer's disease, Parkinson's disease, cancer and will 
contribute to aging. 
B) Electrophiles  
     Electrophilic compounds are attracted to areas of molecules with high electron density 
such as the purine and pyrimidine bases of deoxyribonucleic acid (DNA) [Halliwell and 
Gutteridge 1999]. They are derived from the action of phase 1 reactions of xenobiotics, 
otherwise known as foreign compounds. Phase 1 reactions introduce a polar functional 
group within the foreign molecule by oxidation, involving several enzymes, particularly 
cytochrome P-450, and subsequently convert the foreign molecule into chemically 
reactive electrophilic metabolites (carcinogens).  
 Foreign compounds can be derived from many sources such as cigarette smoking, 
consumption of alcohol or occupational exposure to harmful substances. Examples of the  
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 latter include farmers who are exposed to pesticides and herbicides, or factory workers 
exposed to dye-stuffs [Sheweita and Tilmisany 2003]. When exposed to such 
compounds, our bodies respond by triggering phase 1 and 2 reactions. 
1.1.2 Phase 1 and 2 enzyme responses 
     The metabolism of xenobiotics involves a series of enzymes which function to 
detoxify and convert xenobiotics into more soluble species. The overall metabolic 
process is classified into two phases (phase 1 and 2 reactions). During phase 1 reactions, 
xenobiotics are often converted into reactive electrophiles. If the level of these 
electrophiles in the body is left uncontrolled, they will interact with nucleophilic moieties 
on critical biomolecules such as DNA, forming DNA-adducts. Such adducts may cause 
genetic alterations and activation of proto-oncogenes such as the Bcl-2 gene or 
inactivation of tumour suppressor genes such as p53 [Kensler et al. 1999, Sheweita and 
Tilmisany 2003], subsequently leading to carcinogenesis. In addition, electrophiles cause 
cellular damage by reacting with proteins, causing protein oxidation, and membrane 
lipids, leading to lipid peroxidation. 
     In order to limit the amount of electrophiles, phase 2 enzymes such as GST or UDP-
Glucuronyltransferase (UGTs) are induced and conjugate phase 1 reaction products to 
GSH or D-glucuronic acid, respectively, to form harmless intermediates. The 
intermediates are further metabolized and then excreted from the body [Boyland and 
Chasseaud 1969; Sheweita and Tilmisany 2003] (Figure 1). 
     In summary, phase 1 reactions activate xenobiotics to chemical carcinogens. These 












Figure 1.  Schematic diagram of phase 2 enzyme conjugation reaction catalysed by 
Glutathione-S-Transferase (GST) 
Xenobiotic is conjugated to GSH by the catalyst GST to form water-soluble 
intermediates. The glutathione conjugates are further metabolized into mercapturic acid 
and then excreted.  
 
 
1.1.3 Mechanism of inducing phase 2 gene expression through Nrf2 - Keap1 - ARE    
        signaling pathway 
     As mentioned above, the antioxidant GSH is synthesized by two enzymes, γ-glutamate 
cysteine ligase (γ-GCL) and glutathione synthase (GSS) [Halliwell and Gutteridge 1999]. 
These biosynthetic enzymes as well as GST and other phase 2 enzymes are regulated by 
the Nrf2/ Keap1 /antioxidant response element (ARE) signaling pathway. 
     Nrf2 is a redox-sensitive transcription factor that interacts with the AREs in the 
promoter regions of several genes (e.g. GST, γ-GCL, GSS) collectively known as Nrf 2-
regulated genes [Singh et al. 2006; Kwak et al. 2004]. Keap1 is a cytoplasmic actin-
binding protein bearing specific cysteine residues that act as primary sensors to facilitate 
downstream induction of ARE-driven genes [Kwak et al. 2004].  
xenobiotic + 
Harmful Harmless intermediates product
GSH GSH 
GST 






      Under normal physiological conditions, Keap1 acts as an inhibitor to anchor Nrf2 in 
the cytoplasm through interaction and association with the actin cytoskeleton. The 
sequestered Nrf2 then undergoes ubiquitination and ultimately proteasomal degradation 
[Lee and Surh 2005], thus repressing its ability to induce Nrf2-inducible genes. Upon 
exposure to oxidative stress or electrophiles, Nrf2 dissociates from Keap1 and 
translocates to the nucleus. Within the nucleus, Nrf2 partners with a small Maf protein 
and binds to AREs, causing upregulation of Nrf2-driven genes [Giudice and Montella 
2006; Kwak et al. 2001].  
Two key mechanisms have been proposed on how Keap1 dissociates from Nrf2 and they 
can either work jointly or independently to bring about the dissociation. 
The first mechanism involves modification of Keap1, while the second mechanism 
involves Nrf2 activation. In the former, the presence of oxidative stress or electrophiles 
leads to oxidation or covalent modifications of specific cysteine thiol (sulfhydryl) groups 
in Keap1. This induces structural changes that promote the release of Nrf 2 from its 
inhibitor Keap1 [Lee and Surh 2005]. 
In the second mechanism, Nrf2 is activated by several protein kinase signaling pathways. 
The kinases include protein kinase C (PKC) and three Mitogen-Activated Protein Kinases 
(MAPKs) namely extracellular signal-regulated protein kinase (ERK), c-Jun N-terminal 
kinase (JNK) and p38 MAPK.  Phosphorylation of Nrf2 at serine (S) and threonine (T) 
residues by the above mentioned kinases modify the binding of Nrf2 to Keap1, allowing 
dissociation of the two proteins from each other [Lee and Surh 2005].  
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In addition, the kinase signaling pathways also play another role in promoting the 
dimerization of the phosphorylated Nrf2 with small Maf followed by binding to AREs, 
























Figure 2. Pathway of phase 2 enzyme induction via Nrf2 - Keap1 - ARE signaling 
pathway (Modified from Kwak et al. 2001 and 2004) 
Upon exposure to oxidative stress or electrophiles, Nrf2 dissociates from Keap1 and 
translocates to the nucleus. Within the nucleus, Nrf2 partners with a small Maf protein 
and binds to AREs causing upregulation of Nrf2-driven genes. 
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1.1.4 How do Phase 2 enzymes exert their protective effects? 
 
     Phase 2 reactions are mediated by enzymes which are capable of exerting cell- 
protective effects through inactivating chemical carcinogens by mediating their 
glucoronidation, glutathionylation, sulfation or methylation. The glutathionylation and 
glucoronidation of xenobiotics are carried out by Glutathione-S-transferases and UDP-
Glucuronyltransferase in the presence of GSH and D-glucuronic acid, respectively. 
In addition, other phase 2 enzymes play a role in the synthesis of GSH (γ- Glutamate 
cysteine ligase and Glutathione synthase). 
 
 (a) γ- Glutamate cysteine ligase (γ-GCL) and Glutathione synthase  (GSS) 
     The phase 2 enzymes γ-GCL and GSS mediate the synthesis of GSH, which is a 
water-soluble tripeptide consisting of glutamine, cysteine and glycine residues 
[Townsend et al. 2003]. It exists in two forms - a reduced form (GSH) and an oxidized 
form (GSSG). The ratio (GSSG/2GSH) concentration is used in the calculation of the 
GSH redox potential (Eh) of cells via the Nernst equation [Townsend et al. 2003; Kirlin et 






Equation 1. Nernst Equation   
Eh =  Eo   +      RT   ln   [GSSG] 
 
2F [GSH]2 
In this equation, Eh  at a defined pH is also the electromotive force in millivolts (mV), 
Eo at a defined pH is the standard potential for the redox couple, 
R is the gas constant, T is the absolute temperature and F is the Faraday’s constant. 
[    ] is the concentration  of  GSSG or GSH expressed in molarity 
 7
 Under normal conditions, the Eh is more reducing (or more negative). Under oxidative 
stress when more GSH is converted to GSSG to scavenge free radicals and remove ROS, 
Eh is more oxidizing (or less negative). 
     GSH is one of the most important antioxidant molecules in animal cells and is 
involved in both non-enzymatic and enzymatic reactions [Jones 2002]. Through non-
enzymatic reactions, GSH is able to maintain vitamin C (ascorbate) and vitamin E (α-
tocopherol) in their reduced and functional forms [Jones 2002; Sheweita and Tilmisany 
2003]. Through enzymatic reactions, GSH is involved in metabolizing xenobiotics with 
the aid of GST as well as in the reduction and removal of H2O2 in the presence of GPx 
(EC 1.11.1.9)  [Halliwell and Gutteridge 1999; Knapen et al. 1999] (Figure 3). 
 
  H2O2 + 2GSH                                              GSSG + 2H2O 
GPx 
 
Figure 3. The chemical reaction catalysed by glutathione peroxidase  
  
(b) Glutathione -S- Transferase (GST) and UDP-Glucuronyltransferase (UGTs) 
     GST (EC 2.5.1.18) is a phase 2 enzyme involved in detoxification of electrophilic  
xenobiotics by conjugating them to GSH and rendering them harmless before    





      UGTs (EC 2.4.1.17) also play a role in detoxifying the electrophilic xenobiotics by 
conjugating them to D-glucuronic acid [Sheweita and Tilmisany 2003] to generate 
products that are easier to eliminate from the body. 
 
     In addition to these enzymes, which are involved in the metabolism and inactivation 
of xenobiotics, other phase 2 enzymes play an important role in the cellular defense 
against oxidative stress. The enzymes with antioxidant function include superoxide 
dismutase (SOD), heme oxygenase-1 and GPx. However, the primary focus of this study 
are the phase 2 enzymes involved in the protection from xenobiotics. 
 
1.1.5 Cancer chemoprevention by inducing phase 2 enzyme response 
     As cancer is one of the top leading causes of death for humans, extensive scientific 
research has been conducted to reduce cancer mortality or prevent it, since prevention is 
better than cure. Phase 2 reactions are capable of carcinogen detoxification, thus they are 
one of the most suitable strategies for protection against electrophilic toxicity and the 
neoplastic effects of carcinogens.  
     Normally, upon exposure of the body to procarcinogens, both phase 1 and 2 reactions 
are activated to offset any harmful effects. However the conjugation reactions of phase 2 
and their associated enzymes (GST and UGTs) are frequently suboptimal [Kensler et al. 
2007].  This is because in addition to genetic and hormonal control, the phase 2 reactions 
are also influenced by the individual’s age, nutritional status and the type of xenobiotics 
exposed to [Kwak et al. 2001; Kensler et al. 1999]. 
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       To ensure phase 2 reactions are enhanced without significantly increasing the rate of 
electrophile-generating phase 1 reactions, the administration of external sources of phase 
2 inducing agents is an attractive solution to explore.  
     Dithiolethiones are five-membered cyclic sulfur-containing compounds [Davidson et 
al. 1990] and fall under the category of phase 2 enzyme inducers. They are the most 
broadly effective classes of chemopreventive agents in experimental models of rat, mouse 
and hamster. Oltipraz (4-methyl-5-pyrazinyl-3H-1, 2-dithiole-3-thione) (OPZ), a member 
of dithiolethiones, was shown to prevent carcinogenesis in many organs when they were 
exposed to different carcinogens (Table 1).  
 
 
 Organ References 
Carcinogens Breast Colon Liver Lung  
Aflatoxin   √  Roebuck et al. 1991 
Azoxymethane  √   Rao et al. 1991 
Benzo[a]pyrene    √ Wattenberg and Bueding 1986 
DEN    √ Wattenberg and Bueding 1986 
DMBA √    Boone et al. 1990 
Uracil Mustard    √ Wattenberg and Bueding 1986 
 
 
Table 1.  Chemoprevention of OPZ against experimental cancers  















1.2 Oltipraz (OPZ) 
1.2.1 Origin of OPZ 
      Oltipraz (OPZ) is a potential chemopreventive agent due to its effectiveness in 













  Figure 4. Chemical structure of oltipraz  
                  (4-methyl-5-pyrazinyl-3H-1, 2-dithiole-3- thione [OPZ]) 
 
Rhône-Polenc Santé, a France pharmaceutical company, originally developed OPZ as an 
anti-schistosomal drug and had conducted intensive clinical trials in West Africa, Sudan 
and Brazil in the early 1980s. Its mechanism of action as an antischistomsomal drug is 
believed to be due to depletion of GSH stores and reduction of the activity of both 
glutathione reductase (GR) and GST in the parasites to weaken their oxidant defense 
systems [Nare et al. 1992; Helzlsouer and Kensler 1993].  The consequences are that the 
schistosomes detach from the inner wall of the mesenteric veins and shift to the liver 
[Fleury et al. 1991], making them more susceptible to elimination by the host immune 
cells via ROS [Nare et al. 1992].  
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      Due to multiple side effects and the availability of better alternative anti-schistosomal 
drugs, such as praziquantel, OPZ treatment for the parasite in humans was abandoned. 
The side effects included nausea, abdominal pain or distress, vomiting and diarrhoea and 
more severe effects, such as phototoxicity that aggravates the conditions of paresthesia 
and fingertip pain [Kensler et al. 1999]. 
1.2.2 OPZ as a potential chemopreventive agent 
      During the studies of OPZ’s schistosomicidal effect, Bueding and colleagues made a 
significant discovery. They found that besides lowering the GSH level in the worms, it 
also raised the level of GSH in the host [Bueding et al. 1982]. Elevation of the GSH 
levels in the hosts has led to Bueding’s hypothesis of OPZ as a potential cancer 
chemopreventive agent. His subsequent studies with Wattenberg demonstrated that OPZ 
is capable of inhibiting carcinogenesis in carcinogen-treated mice against a diverse range 
of carcinogens with prior oral administration (Table 1). [Wattenberg and Bueding 1986; 
Boone et al. 1990; Roebuck et al. 1991; Rao et al. 1991].  Further experiments conducted 
by Ansher et al. have shown that administration of OPZ and some other 1,2- dithiole-3-
thiones in mice increased the GSH levels in liver, lung, kidney, forestomach, and upper  
jejunal mucosa [Ansher et al. 1986].   
     Currently OPZ is undergoing a phase II intervention trial to determine its effectiveness 
against aflatoxin, a human liver carcinogen, and its safety for human consumption when 




 1.2.3 Possible mechanisms of action of chemoprotection by OPZ 
     Chemoprevention is defined as the use of natural or synthetic agents to arrest or 
reverse the development of premalignant neoplasia [Kwak et al. 2004]. OPZ is 
considered as a synthetic dithiolethione derivative effective against a diverse range of 
carcinogens and this is attributed to its ability to interact with both phase 1 and phase 2 
reactions.  
     At intermittent high level of OPZ intake, e.g. weekly intake of 500mg, phase 1 
response is inhibited [Camoirano et al. 2001; Wang et al. 1999]. By acting as a 
competitive inhibitor of cytochrome P-450, OPZ prevents the phase 1 enzyme from 
converting xenobiotics into carcinogens [Langouët et al. 2000]. 
      At sustained low level of OPZ intake, e.g. daily intake of 125mg, both phase 1 and 2-
enzyme responses (conjugation with GSH) are activated [Camoirano et al. 2001; Wang et 
al. 1999]. The electrophilic intermediates produced by phase 1 reaction are conjugated to 
GSH by the catalyst GST in phase 2 reactions and then excreted from the body [Halliwell 
and Gutteridge 1999].   
1.2.4 Regulation of phase 2 enzyme response by OPZ  
     It is important to identify and understand the chemical mechanisms by which phase 2 
enzyme inducers (anticarcinogens) initiate the phase 2 enzyme responses. Having such 
knowledge is essential for the development of novel anticarcinogens.  Two general 
hypotheses have been suggested for the mechanism through which OPZ and other 
dithiolethiones exert their action. 
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 In the first hypothesis, OPZ or its metabolites act as electrophiles and induce the 
oxidation of cysteine residues in Keap1 [Lee and Surh 2005], resulting in dissociation of 
Nrf2 from the Keap1-associated E3 ubiquitin ligase complex and transactivation of Nrf2 
antioxidant target genes (Figure 5).   
According to the second hypothesis, OPZ in the presence of glutathione will convert 
molecular oxygen into ROS (e.g. superoxide) [Kim and Gates 1997]. The ROS then act 
as second messengers to mediate an oxidizing reaction to facilitate the dissociation of 
Nrf2 from Keap1. The released Nrf2 will in turn cause upregulation of ARE-driven phase 
2  enzymes (Figure 5). 
The mitochondrial ETC is a major source of cellular ROS [Boveris and Chance 1973]. 
The mitochondrial ETC is also an important determinant of the cellular redox state. Thus, 
it is possible that the mitochondrial ETC plays a role in modulating the phase 2 response, 
which has not previously been investigated. To characterize the involvement of 
mitochondria, lymphoblastic CEM leukemic ρ0 cells that lack a functional ETC were 
used in the present study. 
ρ0 cells lack mtDNA as a result of long-term treatment with ethidium bromide (EtBr), 
which inhibits mtDNA replication [King and Attardi 1989]. MtDNA encodes for 13 
essential subunits of the ETC including seven subunits of mitochondrial complex I 
(NADH dehydrogenase), three subunits of complex IV (cytochrome c oxidase), two 
subunits of complex V (ATPase) and one subunit of complex III (cytochrome b) 
[Alexeyev et al. 2004]. The absence of these 13 mtDNA-encoded subunits leads to a non-
























Figure 5.  Proposed regulation of the phase 2 enzyme response by OPZ in wild type 
cells (Modified from Kwak et al. 2001 and 2004) 
A. According to the first mechanism, it is hypothesized that OPZ or its metabolites acts 
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of Nrf2 and its subsequent nuclear translocation and activation of   Nrf2 – regulated 
genes.  
B. The second mechanism proposes that the OPZ-induced oxidation of cysteine residues 




1.3  Aims of the study 
The aim of the study was to characterize the mechanism through which OPZ acts as a 
chemopreventive agent in the Keap1-NRF2 pathway (see Figure 6). To this end, the 
following specific questions will be addressed:  
1) Does OPZ induce a phase 2 response in the lymphoblastic leukemia CEM cell line?  
2) Is a functional mitochondrial ETC required for the phase 2 induction by OPZ? 
3) Does OPZ pretreatment protect CEM cells from electrophile-induced mitochondrial 
and cellular damage? 


































Figure 6.  Regulation of phase 2 enzyme response by OPZ in cells lacking 
mitochondrial DNA (mtDNA) (Modified from Kwak et al. 2001 and 2004) 
 (NB: The electron microscopic image of CEM ρ0 cell mitochondria was provided by 
fellow colleague, Lu Chao)  
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2.   MATERIALS AND METHODS 
 
 
2.1 Chemicals and reagents  
      All chemicals were reagent grade and were obtained from Sigma chemical company 
unless otherwise stated. OPZ was obtained from LTK Laboratories (St. Paul Minnesota) 
and commercial kits used to measure GSH and GSSG levels and GST activity were from 
Cayman Chemicals (Ann Harbour, MI, USA) 2’-7’-Dichlorodihydrofluorescein diacetate 
(DCFDA) and Tetra-methyl rhodamine methyl ester (TMRM) were obtained from 
Molecular Probes (Eugene Oregon). Cytochrome c oxidase subunit II (COX II) 
polyclonal antibody was from (Cayman chemical, Ann Arbor, MI, USA) and secondary 
antibody (Goat anti-rabbit) from BD Biosciences. Monoclonal anti-beta-actin was from 
Sigma-aldrich and the secondary antibody (Goat Anti-Mouse) was from Upstate cell 
signaling solutions, Lake Placid, NY. 
2.2 Cell lines and culture 
 
     All cell lines used in the research were grown at 37oC in a humidified gas mixture 
containing 5% CO2.  
2.2.1 CEM parental (ρ+) cells 
 
     CEM parental (ρ+) cells (a gift from Professor Shazib Pervaiz) were originally 
obtained from ATCC. CEM parental cells are lymphoblastic suspension cells and are a 
good model to characterize the phase 2 enzyme response. The cells were cultured in 
RPMI (Roswell Park Memorial Institute) 1640 (Hyclone, Logan, UT)  and 10% fetal 
bovine serum, 2mM L-glutamine, 1% penicillin-streptomycin (Gibco, Grand Island, NY)  
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 and 0.02mg/ml geneticin. Cells were passaged daily to maintain them in log-phase 
growth and kept at a nominal concentration of 2.5- 5 x105/ ml.   
 
 
2.2.2 Generation of Cells lacking mitochondrial DNA 
 
     CEM ρ0 cells were derived from CEM parental cells by culturing in the presence of 50 
ng/ml of ethidium bromide (EtBr, 3,8-diamino-5ethyl-6-phenylphenanthridinium 
bromide) for 4 weeks. These ρ0 cells were then cultured in RPMI 1640 medium with 1 
mM pyruvate and 50μg/ml uridine and regularly monitored for potassium cyanide 
(KCN)-sensitive oxygen consumption.  
2.2.2.1 Addition of DNA intercalator 
     As the ethidium ion is a lipophilic cation that strongly concentrated in mitochondria 
rather than nuclei, it preferentially intercalates into and inhibits replication of mtDNA by 
hindering its synthesis by DNA polymerase gamma [Okamaoto et al. 2003].  
2.2.2.2 Why additional pyruvate and uridine are essential? 
   Since mammalian ρ0 cells have become pyruvate and pyrimidine auxotrophic, they are 
incapable of surviving and proliferating even in presence of high glucose. Although ρ0 
cells generate a large amount of pyruvate from the glycolytic breakdown of glucose, the 
pyruvate is reduced to lactate by NADH-linked lactate dehydrogenase and does not enter 
the tricarboxylic acid (TCA) cycle in the mitochondrial matrix. This anaerobic glycolysis 
therefore reduces the amount of pyruvate available to produce metabolic intermediates 
via the TCA cycle and hence additional pyruvate must be supplied [King and Attardi 
1989]. 
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      In ρ0 cells, the enzyme, dihydroorotate dehydrogenase that is involved in pyrimidine 
biosynthetic pathway is inactive due to absence of a functional mitochondrial electron 
transport chain [King and Attardi 1989; Bayona-Bafaluy et al. 2002]. Providing these 
cells with uridine will guarantee the production of pyrimidine bases essential for survival. 
2.3 Verification of Cells lacking mitochondrial DNA 
       
       2.3.1 Measurement of cellular oxygen consumption     
  
      Oxygen consumption was determined polarographically using a Clarke-type oxygen 
electrode (Hansatech Instruments Ltd, Norfolk, England). The oxygen electrode was 
liquid-calibrated by addition of one or two crystals of sodium dithionite into the air 
saturated distilled water in the reaction vessel. The dithionite will react with the dissolved 
oxygen according to Figure 7 to deplete it to the minimum amount also known as the N2 
line.  
 
Na2S2O4 + O2 + H2O                                               NaHSO4 + NaHSO3 
 
Figure 7. Reaction between dithionite and dissolved oxygen 
 
Contents of the vessel were then removed, rinsed and replaced by air-saturated water to 
obtain the maximum amount of oxygen in the vessel or also known as the air-line. The 
difference between the air-line and the N2 line represents the oxygen concentration of 
water in the reaction vessel. 
10ml of cells at a density of 1.22 X 106 /ml were centrifuged at 600g for 3 minutes. 
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  The supernatant was discarded and the pellet was resuspended in 1ml of cell culture 
media. 
After the cells are loaded into the oxygraph reaction chamber, a stable trend is obtained 
before 0.025μM of KCN is added, to determine the KCN sensitivity of cellular oxygen 
consumption. 
      2.3.2 Western blot analysis of cytochrome c oxidase subunit II (COX II)   
               expression from whole cell lysate 
      7.5ml of cells at 1 X 106 were centrifuged at 600g, 3 minutes, washed once with ice-
cold phosphate-buffered saline (PBS) and lysed in cell lysis buffer (20mM Tris-HCl (pH 
7.5), 150mM NaCl, 1mM Na2EDTA, 1mM EGTA, 1% Triton, 2.5mM sodium 
pyrophosphate, 1mM β-glycerophosphate, 1mM Na3VO4, 1μg/ml leupeptin, 10μm 
PMSF, Cell Signaling Technology, Trask Lane Danvers, MA). The cell lysate was 
centrifuged at 600g for 5 minutes at 4oC to remove cellular debris and the supernatant 
was collected as the whole cell lysate. The protein concentration of the lysate was 
measured by BioRad DC protein assay and 40μg protein of each sample was separated by 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) on 8% gels. 
They were then transferred to a nitrocellulose membrane and blocked with 5% non-fat 
milk in 0.05% TBST for 1 hour. Membranes were probed with primary antibody against 
COX II (Cayman chemical, Ann Harbor, MI, USA) with 1: 500 dilution for 20 hours at 
4oC  and secondary horseradish peroxidase-conjugated goat anti-rabbit antibody (B.D. 
Biosciences) with 1:7500 dilution for 1 hour at 25oC. Anti-β-actin antibody was used as 
loading control at 1: 5000 dilution for 1 hour at 25oC . Chemiluminescence visualization  
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was performed using an enhanced chemiluminescence (ECL) - detection kit according to 
the manufacturer’s instructions (Pierce, USA). 
 
2.4 Assessment of phase 2 enzyme response in ρ0 cells 
2.4.1 OPZ treatment of CEM ρ+ and ρ0 cells 
      Both CEM ρ+ and ρ0 cells were pretreated with 50μM OPZ for 16.5 hours prior to 
experimentation unless stated.  
      2.4.2 Subcellular fractionation  
 
      Mitochondrial isolation was performed according to [Yang et al. 1997] with 
modifications. 
40ml of cells at a density of 1 X 106 were harvested by centrifugation at 600g for 3 
minutes at 4oC and washed with ice-cold (4oC) PBS and resuspended in MES buffer  
(0.2M 2-(N-morpholino) ethanesulphonic acid, 0.05M phosphate, and 1mM EDTA, pH 
6) provided in the glutathione assay kit (Cayman chemical, Ann Harbor, MI, USA). 
The cells were homogenized approximately 5 to 6 times with a 271/2 gauge needle 
attached to a 1 ml syringe until 80% of them were broken. The amount of broken cells 
can be estimated by loading a small volume of trypan blue stained lysate onto a 
haemacytometer and viewed under microscope. As viable cells exclude this dye, whereas 
non-viable cells stain due to breakage of their cell membranes, the percentage of broken 
cells is equivalent to the proportion of cells that are stained blue. 
The homogenate was centrifuged at 800g for 3 minutes at 4oC to remove nuclei and 
unbroken cells. The supernatant was centrifuged at 11,000g for 10 minutes at 4oC and the 






2.4.3 Glutathione Nernst redox potential (Eh) measurement 
 
      Glutathione Nernst redox potential (Eh) was calculated using the Nernst equation 
using a cell volume of 7μl per million cells [Kirlin et al. 1999] and Eo at pH 7.0 was 
taken as - 240mV [Rost and Rapoport 1964] (Equation 1) 
Both GSH and GSSG levels were measured using a commercial kit (Cayman Chemicals, 
Ann Harbor, MI, USA). The kit makes use of the GSH-GSSG recycling assay as 
designed by Tietze [Tietze 1969] to quantify GSH. DTNB (5,5’-dithiobis-2-nitribenzoic 
acid, Ellman’s reagent) is reduced by the sulfhydryl group of GSH to produce the  
chromophore, 5-thio-2-nitrobenzoic acid (TNB). The mixed disulfide, GSTNB (between 
GSH and TNB) that is produced concomitantly is reduced by glutathione reductase to 
recycle the GSH to produce more TNB (Figure 8A). The rate of TNB production is 
directly proportional to this recycling reaction which is in turn directly proportional to the 
concentration of GSH in the sample. The amount of TNB is measured 
spectrophotometrically as absorbance at 405nm.  
To determine the amount of GSSG exclusive of GSH in the sample, GSH was first 
derivatized in the sample using 2-vinylpyridine [Griffith 1980].  The GSSG was then 
reduced to GSH by glutathione reductase  (Figure 8B), followed by reaction with DTNB 




























Figure 8. GSH – GSSG recycling  
NB: NADP+ stands for nicotine adenine dinucleotide phosphate 
       NADPH is the reduced nicotine adenine dinucleotide phosphate 
         
2.4.4 Measurement of Glutathione- S- Transferase activity 
 
     GST activity was measured using a commercial kit that was also obtained from 
Cayman Chemicals. The activity can be measured by the conjugation of 1-chloro-2,4,-
dinitrobenzene (CDNB) with reduced glutathione (GSH). The conjugation is 
accompanied by an increase in absorbance at 340nm. The rate of this increase is directly 
proportional to the GST activity in each sample. 
2.5 Investigation of OPZ-mediated protection from eletrophile induced damage 
2.5.1 Diethylmaleate treatment of CEM ρ+ and ρ0 cells 
 
     Diethylmaleate (DEM) is a GSH depleting agent and does it by conjugating GSH to it  
in presence of GST  [West et al. 2000], leading to depletion of cellular GSH [Mitchell et 
al .1983]  
Glutathione Reductase 
+ NADPH 
GSH DTNB TNB 
TNB GSTNB 
 GSSG + NADPH  + H+                                              2GSH + NADP+ 
Glutathione  Reductase B 
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Aliquots of CEM ρ+ and ρ0 cells, which were incubated in RPMI ± 50μM OPZ for 16.5 
hours, were treated with either RPMI (control) or 5mM of DEM for 10 hours. 
     Cell viability was determined at 1 hour intervals during the time course of the 
experiment.  Cell viability was determined by trypan blue analysis and expressed as  
percentage (%). Cell viability (%) is calculated as ratio of the number of viable cells to  





Cell viability (%)          =         Total viable cells              X           100% 
                                             Viable and Dead cells 
 
Equation 2. Equation for cell viability calculation 
 
2.5.2 Flow cytometry analysis of ROS production 
 
      Flow cytometry determinations for cellular H2O2 formation were performed as 
described previously [Armstrong et al. 2004]. Both CEM ρ+ and ρ0 cells were treated 
with DEM for 0, 10, 20, 30, 40, 50, and 60 minutes, loaded with 10μM DCFDA for 15 
minutes at 37oC, washed with PBS containing 10mM glucose, and analyzed immediately 
by flow cytometry using the fluorescein isothiocyanate (FITC) channel (log mode). In 
each analysis, 10,000 events were recorded. DCFDA is a fluorescent dye that breaks 
down by intracellular esterases to a nonfluorescent polar derivative, DCFH, which is then 
converted into highly fluorescent 2’,7’-dichlorofluorescein (DCF) upon reaction with 
cellular H2O2 [Nelson et al. 2002]. This fluorescence was then measured by flow 
cytometry. A shift in the histogram of treated cells towards the right as compared to the 
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untreated cells indicates a higher DCF fluorescence and hence a higher H2O2 
concentration. 
     To measure cellular superoxide production by flow cytometry, CEM ρ+ and ρ0 cells 
treated with oltipraz at concentrations ranging from 10μM to 50μM for 16.5 hours were 
loaded with 10μM dihydroethidium (DHE) for 15 minutes at 37°C. The red fluorescence 
was analyzed immediately by flow cytometry using the PE-Texas red channel (log 
mode). In each analysis, 10,000 events were recorded. In the presence of superoxide, 
DHE will form a two-electron oxidized product, ethidium. Ethidium then binds to DNA 
and emits red fluorescence (excitation, 500–530nm; emission, 590–620nm) that is 
measured by the flow cytometry [Zhao et al. 2003]. 
2.5.3 Transmission Electron microscopy  
 
      CEM cells in the logarithmic proliferation phase were cultured in RPMI 1640 in the 
presence of DEM (5mM) ± oltipraz for 120 minutes and were fixed with 2.5% 
glutaraldehyde in 0.1M cacodylate buffer, pH 7.4, at room temperature for 1 hour. The 
cells were prepared for electron microscopic as described previously [Armstrong et al. 
2004]. Briefly, cells were washed with 0.1M cacodylate buffer and post-fixed with 1% 
osmium tetraoxide in 0.1M cacodylate buffer. Finally, the cells were dehydrated with 
graded series of ethanol and embedded in LX112. Thin sections were prepared and 
stained with uranyl acetate. Specimens were examined on a JEOL 1000X electron 
microscope operating at 80 kV, carried out at Electron microscopy unit of Temasek Life 




 2.5.4 Flow cytometry analysis of Mitochondrial membrane potential (Δψm) 
      For the determination of Δψm, cells were treated with DEM for 0, 30, 60, 90, 120, and 
150 minutes, and loaded with 250nM TMRM (TMRM is a cationic dye which 
accumulates within mitochondria in accordance with the Δψm Nernst potential) for 15 
minutes at 37oC and red fluorescence was determined by flow cytometry using the 
phycoerythrin (PE) channel [Armstrong et al. 2004]. The protonophore carbonyl-CCCP 
(10μM) was used to dissipate the chemiosmotic proton gradient (ΔμH+) and served as a 
control for loss of Δψm. In each analysis, 10,000 events were recorded. 
 
2.6 Statistical Analysis  
 
      Statistical analyses were performed using one-way ANOVA and p values <0.05 were 
considered significant. P value is defined as the probability of obtaining a set of results if 
the null hypothesis is true (where null hypothesis defines there is no difference between 
sets of data). By convention, a p value of less than 0.05% is often regarded as evidence 
for rejecting the null hypothesis, which means that there is a significant difference 




















3.  RESULTS 
 
 
3.1 Verification of Cells lacking mitochondrial DNA  
 
     In order to determine whether the OPZ-mediated phase 2 signaling response is 
mitochondrially redox regulated, CEM cells lacking mitochondrial DNA (ρ0) were 
created by treating them with 50ng/ml of EtBr for 4 weeks in presence of 1mM pyruvate 
and 50μg/ml uridine.  
Two of the more common tests were used to verify that majority of mtDNA is absent 
in these EtBr treated cells before they were use for experiments. 
3.1.1 Measurement of Oxygen consumption     
     Oxygen consumption of both ρ+ and ρ0 cells was determined polarographically by a 
Clark-type oxygen electrode at 37oC (Figure 9A) and their rate of consumption 
compared.  The O2 consumption of ρ0 cells was found to be 27.2 % compared to parental 




























                
               Figure 9A.  A representative oxygraph trace showing oxygen consumption    
               of CEM  cells before and after 4 weeks of  chronic EtBr treatment.  
               The green trace represents oxygen consumption of CEM ρ+  and the orange  
                trace represent the oxygen consumption of  CEM ρ0 cells.  The results are    
                expressed in nmol/ml. KCN was added when a stable trend is obtained for  
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                  Figure 9B. Average oxygen consumption rate of ρ+ and ρ0  over 4 weeks  
                  Average oxygen consumption of CEM ρ+ and ρ0  treated continuously with   
                  50ng/ml EtBr for 4weeks. They are expressed as nmol/min/107 cells as the   





      3.1.2 Western blot analysis of cytochrome c oxidase subunit II (COX II)   
               expression from whole cell lysate 
     To demonstrate that continuous EtBr treatment has depleted the majority of mtDNA 
and terminated the production of mitochondrial encoded proteins of the ETC, expression 
of COX II was detected by western blot. From Figure 10, the expression level of COX II 






















     Figure 10. Western blot showing the absence of COX II in whole cell extract of ρ0       
     cells 
     Western blot of whole cell lysate derived from CEM cells treated with different weeks   
     (week 0, 1, 2, 3, 4) of EtBr and were probed for  COX II. Cells treated continuously  




3.2 The phase 2 enzyme response is intact in ρ0 cells 
     To determine whether the phase 2 enzyme response is intact in cells lacking mtDNA, 
GSH (total and mitochondrial), GSSG levels and GST activity of both CEM ρ+ and ρ0 
cells were measured as described in the methodology (section 2.4.3 and 2.4.4). 
 
3.2.1 GSH levels are increased in CEM ρ+ and ρ0 cells after treatment with OPZ 
 
          GSH and GSSG levels and GSH redox (Eh) potential were determined on aliquots of CEM    
ρ+ and ρ0 cells pretreated with OPZ in presence or absence of DEM. OPZ pretreatment 
increased GSH levels in ρ+ cells from 60.8 ± 4.2 nmol/mg protein to 85.4 ± 5.9 nmol/mg 
protein (P<0.05) and increased GSH levels in ρ0 cell from 38.9 ± 2.2 nmol/mg protein to 64.7 
± 5.2 nmol/mg protein (P<0.05) (Figure 11A).  This represents an approximate 40 % increase 
in GSH levels in ρ+ cells and an approximate 60 % increase in GSH in ρ0 cells.  




      Having demonstrated upregulation of cellular GSH by OPZ, it was investigated whether OPZ 
can protect cells from DEM-induced depletion of cellular GSH. DEM treatment for 2 hours 
significantly reduced GSH levels (>95%) in both ρ+ (from 60.8 ± 4.2 to 0.24 ± 0.07 nmol/mg 
protein) and ρ0 (from 38.9 ± 2.2 nmol/mg protein to 0.47 ± 0.07 nmol/mg protein) cell lines.  
Pretreatment of cells with OPZ reduced the GSH depletion after DEM treatment from 99.6% to 
74% in ρ+ and from 99% to 84% in ρ0 cells.  The GSH levels after OPZ pretreatment and DEM 
incubation were 15.9 ± 1.2 nmol/mg protein in ρ+ cells and 6.3 ± 1.0 nmol/mg protein in ρ0cells 
(Figure 11B). These results indicate that OPZ pretreatment results in partial protection from 
DEM-induced GSH depletion in both ρ+ and ρ0 cells. Interestingly, although OPZ increased 
cellular GSH concentrations in ρ+ and in ρ0 cells to similar degrees, the protective effect of OPZ 

























Figure 11.  Total GSH levels in CEM ρ+ and ρ0 cells before and after OPZ and DEM 
treatment 
A. CEM parental ρ+ and ρ0 cells were incubated in RPMI ± 50μM OPZ for 16.5 hours. 
B. CEM parental ρ+ and ρ0 cells were treated with DEM for 0 or 120 minutes or preincubated 
in RPMI ± 50μM OPZ for 16.5 hours and then treated with DEM. GSH levels were 
determined on these samples as described under Materials and Methods. The GSH 
concentration is plotted as nanomole per milligram protein. Data are expressed as means ± 













































      OPZ pretreatment increased mitochondrial GSH levels in ρ+ cells from 6.2 ± 0.3 nmol/mg 
protein to 7.6 ± 0.5 nmol/mg protein (P<0.05) and increased mitochondrial GSH levels in ρ0 
cells from 4.3 ± 0.5 nmol/mg protein to 5.1 ± 0.2 nmol/mg protein (P<0.05) (Figure 12A).  
This represents an approximate 20 % increase in mitochondrial GSH levels in both ρ+ and ρ0 
cells. DEM treatment for 2 hours significantly reduced mitochondrial GSH (>95%) in both 
ρ+ (from 6.2 ± 0.3 to 0.31 ± 0.04 nmol/mg protein) and ρ0 (4.3 ± 0.5 to 0.26 ± 0.02 nmol/mg 
protein) cell lines.  Pretreatment of cells with OPZ reduces mitochondrial GSH depletion 
after DEM treatment since mitochondrial GSH levels were 1.156 ± 0.5 nmol/mg protein in ρ+ 
cells and 0.389 ± 0.1 nmol/mg protein in ρ0cells (Figure 12B). However, in both ρ+ and 
ρ0cells, the protective effect of OPZ in mitochondria was much less pronounced compared to 
whole cells. Furthermore, as observed above for cellular GSH, OPZ conferred less protection 





























Figure 12.  Mitochondrial GSH levels in CEM ρ+ and ρ0 cells before and after OPZ 
and DEM treatment 
A. CEM parental ρ+ and ρ0 cells were incubated in RPMI ± 50μM OPZ for 16.5 hours.  
B. CEM parental ρ+ and ρ0 cells were treated with DEM for 0 or 120 minutes or preincubated 
in RPMI ± 50μM OPZ for 16.5 hours and then treated with DEM. GSH levels were 
determined on these samples as described under Materials and Methods. The GSH 
concentration is plotted as nanomole per milligram protein. Data are expressed as means ± 
SEM (n = 3). (*P < 0.05). 
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  3.2.2 Glutathione Nernst redox potential (Eh) measurement 
 
     To determine the effects of OPZ on the redox state of the GSH/GSSG pool, reduced 
(GSH) and oxidized (GSSG) glutathione were measured and the GSH to GSSG ratio was 
calculated as the Nernst potential as described in the Materials and Methods. 
It was found that under basal conditions the redox potential in ρ0 cells was slightly higher 
compared to ρ+ cells, indicating a slightly more oxidized glutathione redox state in ρ0 
cells. DEM treatment resulted in an increase (to less negative values) of the redox 
potential in both CEM parental ρ+  and ρ0 cells. The effect in ρ+ and ρ0 cells was prevented 
when cells were pretreated with OPZ. OPZ treatment by itself resulted in a small 
decrease in the GSH redox potential in both ρ+ and ρ0 cells (Table 2). 
 
 Nernst GSH redox potential Eh(mV) ρ+ ρ0 
control -264.3 ± 13.6 
 
-246.6 ± 12.7 
 
DEM -138.5 ± 5.1 
 
-155.7 ± 10.1 
 
OPZ -287.6 ± 12.1 
 
-272.4 ± 10.1 
 
OPZ +DEM  -234.6 ± 11.1 
 
-202.8 ± 8.8 
 
 
TABLE 2. Nernst GSH redox potential Eh (mV) 
Aliquots of CEM parental ρ+ and ρ0 cells (approximately 4 x 106/ml) preincubated in 
RPMI  ± 50μM OPZ for 16.5 hours and then treated with DEM or RPMI (control) for 0, 
or 120 minutes.  GSH and GSSG concentrations were determined by assays described in 
the methods section. The GSH redox potential (Eh) in mV was calculated using the 










3.2.3 GST levels are increased in CEM ρ+ and ρ0 cells after  treatment with OPZ 
 
     OPZ is known to increase the expression of phase 2 detoxification enzymes. To determine its 
effect on GST, GST enzyme activity was measured and found to increase from 9.4 ± 0.6 
nmol/min/mg protein to 14.9 ± 0.3 nmol/min/mg protein in ρ+ cells treated with OPZ for 16.5 
hours (P<0.05). This represents an approximate 60% increase in GST activity. GST activity 
increased from 13.5 ± 0.2 nmol/min/mg protein in ρ0 cells to 18.6 ± 0.2 nmol/min/mg protein in 
CEM ρ0 cells after treatment with oltipraz for 16.5 hours (approximately 40%) (P<0.05)  








































Figure 13. GST activity in CEM ρ+ and ρ0 cells before and after OPZ treatment  
      CEM parental ρ+ and ρ0 cells were incubated in RPMI ± 50μM OPZ for 16.5 hours and GST      
activity was determined as described in methods section. GST activity in parental CEM ρ+ 
cells was 9.4 ± 0.6 nmol/min/mg protein compared to 14.9 ± 0.3 nmol/min/mg protein after 
treatment with OPZ. GST activity of CEM ρ0 cells was 13.5 ± 0.2 nmol/min/mg protein 




3.3 OPZ dependent protection from electrophile stress in ρ+ and ρ0 cells 
      To determine whether the phase 2 enzyme response in cells lacking mtDNA is 
functional, both CEM parental ρ+ and ρ0 cells were pretreated with OPZ, followed by 
exposure to DEM.  Flow cytometry analysis of the ROS production and mitochondrial 
membrane potential of the cells with and without treatment were carried out according to 
section 2.5.2 and 2.5.4. Effects of OPZ and DEM on mitochondrial cristae of CEM cells 
was observed by performing transmission electron microscopy on the samples. 
3.3.1 OPZ treatment prevents ROS production upon GSH depletion with DEM 
     Cellular ROS production was determined in cells by monitoring the fluorescence of the H2O2 
sensitive dye DCF. Increased DCF fluorescence, a measure of intracellular oxidation and ROS 
production [Armstrong et al. 2004], was determined as a shift in DCF fluorescence to the right 
on the x axis of the Fluorescence-activated cell sorting (FACS) histogram. CEM parental ρ+ and 
ρ0 cells were incubated in RPMI ± OPZ. Figure 14A shows representative DCF FACS 
histograms of CEM cells stained with DCFDA and analyzed using FITC channel as described in 
the Materials and Methods section. Aliquots of ρ+ and ρ0 cells (2 x 106/ml) were treated with 
DEM for 0, 10, 20, 30, 40, 50 and 60 minutes, washed in PBS and suspended in PBS containing 
10mM glucose. Cells were loaded with 10μM DCFDA for 15 minutes and fluorescence was 
measured by flow cytometry using the FITC channel. Figure 14A shows that DEM treatment 
caused the DCF fluorescence to shift right on the x axis of the FACS histogram indicating 
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increased ROS production in both ρ+ and ρ0 cells. This was prevented when both cell types were 
preincubated with OPZ.   
 
Figure 14B shows a bar graph summarizing the mean DCF fluorescence (a.u.) of CEM parental 
ρ+ and ρ0 cells before and after treatment with DEM ± OPZ determined from mean fluorescence 
(a.u.) of FACS histograms as described above. As apparent in Figure 14B, the OPZ-mediated 
protection was slightly more pronounced in ρ+ compared to ρ0 cells.  
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Figure 14. Effects of OPZ pretreatment on oxidation (ROS) production in ρ+ and ρ0  cells 
after GSH depletion.  
A. CEM parental ρ+ and ρ0 cells were incubated in RPMI ± 50μM OPZ for 16.5 hours. Figure 
shows representative DCF FACS histograms of CEM cells stained with DCFDA and analyzed 
using FITC channel as described in the methods section. Aliquots of ρ+ and ρ0 cells (2 x 106/ml) 
were treated with DEM for 0, 10, 20, 30, 40, 50 and 60 minutes, washed in PBS and suspended 
in PBS containing 10mM glucose. Cells were loaded with 10μM DCFDA for 15 minutes and 
fluorescence was measured by flow cytometry using the FITC channel. Representative example 
from 3 independent experiments. In each analysis, 10,000 events were recorded. 
B. Bar graph showing mean DCF fluorescence (a.u.) of CEM parental ρ+ and ρ0 cells determined 
from mean fluorescence (a.u.) of FACS histograms as described above. In each analysis, 10,000 
















3.3.2 GSH depletion causes ultrastructural changes in mitochondrial cristae of CEM cells  
   which is blocked by pretreatment with OPZ 
     Figure 15A, shows typical mitochondrial structure in untreated parental CEM cells. Inset 
arrow heads point to mitochondrial cristae showing typical crystal ultrastructure of CEM cell 
mitochondria. Figure 15B shows mitochondria of cells treated with DEM; inset arrowheads point 
to i) small fragmented electron dense mitochondrion, ii) mitochondrion showing increased 
electron density of remodeled mitochondrial cristae and iii) typical vacuolated mitochondrion. 
Figure 15C shows mitochondria of cells pretreated with 50μM OPZ for 16.5 hours and then 
treated with DEM for 120 minutes; inset arrow heads point to mitochondrial cristae. EM results 























































Figure 15.  Representative electron micrographs (EM) of CEM cells with and 
without OPZ pretreatment followed by DEM treatment 
 CEM cells incubated in RPMI  ± 50μΜ OPZ for 16.5 hours and then treated with DEM 
or RPMI (control) for 0, or 120 minutes.   
Figure 15A shows mitochondria in control cells; inset arrow heads point to mitochondrial 
cristae.   
Figure 15 B shows mitochondria of cells treated with DEM; inset arrowheads point to 
 i) fragmented electron dense mitochondrion, ii) mitochondrion showing increased 
electron density of mitochondrial cristae and iii) vacuolated mitochondrion.  
Figure 15 C shows mitochondria of cells treated with DEM + OPZ; inset arrow heads 
point to mitochondrial cristae. EM results suggest that oltipraz preserves mitochondrial 
cristae (the sites of electron transport and oxidative phosphorylation) after GSH depletion 
compared to DEM treatment alone in which the mitochondria ultrastructure is 













3.3.3 GSH depletion causes loss of Δψm in CEM ρ+ and ρ0 cells which is blocked by  
   pretreatment with OPZ  
     Figure 16 shows the Δψm of ρ+and ρ0 cells determined by monitoring the fluorescence of cells 
loaded with the membrane potential dye TMRM. Decreased TMRM fluorescence, corresponding 
to a decreased Δψm, is detected as a shift in TMRM fluorescence to the left on the x axis of the 
FACS histogram. Figure 16 shows that cells with decreased TMRM fluorescence are 
significantly increased in number approximately 90 minutes after treatment with DEM and this 
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       Figure 16. Effects of OPZ pretreatment on mitochondrial membrane potential (Δψm )   
       in ρ+ and ρ0  cells after GSH depletion. 
Representative flow cytometric analysis of CEM cells stained with TMRM and analyzed 
using the PE channel as described in the Methods section. CEM parental ρ+ and ρ0 cells 
were incubated in RPMI ± 50µM OPZ for 16.5 hours. The figure shows representative 
FACS histograms of CEM cells loaded with TMRM and analyzed using PE channel as 
described in the methods section. Aliquots of ρ+ and ρ0 cells (2 x 106/ml) were treated 
with DEM for 0, 30, 60, 90, 120 and 150 minutes, washed in PBS and suspended in PBS 
containing 10mM glucose. Cells were loaded with 250nM TMRM for 15 minutes and red 
fluorescence was measured by flow cytometry using the PE setting. A representative 
example from at least 3 independent experiments is shown. In each analysis, 10,000 






3.3.4 OPZ blocks cell death in CEM ρ+ and ρ0 cells after GSH depletion 
     Since OPZ blocked ROS production and preserved mitochondrial structure and Δψm 
of CEM cells, we determined cell viability after DEM treatment. Figure 17 shows that 
oltipraz pretreatment significantly preserved cell viability in ρ+ and ρ0 cells after 


















Figure 17. Effects of OPZ on cell viability of CEM ρ+ and ρ0 cells after GSH 
depletion 
CEM cells were incubated in RPMI ± 50μM OPZ for 16.5 hours. Aliquots of cells were 
treated with either RPMI (control) or DEM for 10 hours. The cell viability was 
determined at 1 hour intervals during the time course of the experiment. Controls were 
omitted for clarity. Cell viability was determined by trypan blue analysis. Data are 
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3.4 Effects of OPZ on superoxide production 
     It has been suggested that OPZ induces superoxide via direct interaction with GSH 
[Velayutham et al. 2005a,b]. Therefore the effect of OPZ on cellular superoxide and 
H2O2 production was measured, as described under Materials and Methods (section 
2.5.2).      
OPZ was found to increase cellular superoxide production in a dose dependent manner in 
both ρ+ and ρ0 cells as measured using DHE. There were no significant differences in the 
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OPZ also increased the cellular H2O2 concentration in both ρ+ and ρ0 cells as measured 
using DCF fluorescence. Although the basal H2O2 concentration was higher in ρ0 cells, 
OPZ treatment resulted in a similar increase in DCF fluorescence in ρ+ (56 %) and  
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Figure 19.  FACS histograms of CEM ρ+ and ρ0 cell of DCF fluorescence before and 
after treatment with 50μM OPZ for 16.5 hours.  
Figure 19A shows representative FACS histograms for the DCF fluorescence in CEM 
parental ρ+ and ρ0 cell before and after treatment with 50μM OPZ for 16.5 hours.  
Figure 19B shows a bar graph of the mean DCF fluorescence (a.u.) of CEM parental ρ+ 
and ρ0 cells before and after treatment with 50μM OPZ for 16.5 hours.  Data are 
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4.  DISCUSSION 
 
 
     Induction of the phase 2 enzyme responses is important for detoxification of 
carcinogens. The detoxification process is initiated by conjugation of carcinogens with 
GSH, catalyzed by GST, or with D-glucuronic acid, catalyzed by UGT, to increase their 
solubility and allow their excretion [Burchell and Coughtrie 1997; Sheweita and 
Tilmisany 2003]. To ensure efficiency of the phase 2 enzyme responses are at their 
optimal rate, external phase 2 inducing agents such as OPZ can be introduced. Presence 
of OPZ will thus enhance carcinogen detoxification. Given that OPZ is considered as a 
promising cancer chemopreventive agent, it is important to have knowledge of the 
molecular mechanism through which OPZ initiate phase 2 enzyme responses. 
     In this study, we used lymphoblastic leukemic CEM ρ0 cells and OPZ to first 
determine whether the phase 2 enzyme response was intact in cells lacking a functional 
ETC. Secondly, we determined whether the response is able to enhance GSH-dependent 
systems to protect against endogenous oxidative stress caused by DEM. Lastly, we 
investigated our main aim, whether the OPZ-mediated phase 2 signaling response is  
regulated by redox signals originating from mitochondria. 
 
4.1 Generation of CEM ρ0 cells 
     The ρ0 cells used in this study were generated by long term treatment with EtBr 
according to published protocols (King and Attardi 1989). The absence of a functional 
ETC was confirmed by measuring cellular oxygen consumption by polarography and 
cytochrome c oxidase subunit II (COX II) expression by Western blotting. As shown in 
Figure 9, oxygen consumption was markedly decreased after 4 weeks of EtBr treatment. 
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Although there was significant residual respiratory activity in the ρ0 cells, this was largely 
KCN insensitive, indicating that this was not due to mitochondrial ETC activity. A 
marked decrease in mitochondrial DNA encoded COX II protein expression was 
observed after two weeks of EtBr treatment, enabling us to use these ρ0 cells to 
investigate the role of the mitochondrial ETC in regulating the phase 2 response. 
4.2 The phase 2 enzyme response is intact in CEM ρ0 cells 
 
     As both GSH and GST are involved in the phase 2 conjugation reaction, an intact 
phase 2 enzyme response will cause an increase in the level of GSH and activity of GST 
via the Nrf2-Keap1-ARE signaling pathway. To determine whether this response is intact 
in CEM ρ+ and ρ0  cells, the GSH concentration and GST activity were measured in both 
cell types after the addition of the phase 2 inducing agent OPZ. Previous studies have 
shown that OPZ is able to increase the level of GSH biosynthetic enzymes and GST 
[Davidson et al. 1990; Primiano et al. 1996; Langouët et al. 1996]. In agreement with 
these reports we found that OPZ significantly increased GSH levels and GST activity in 
CEM ρ+ cells  (Figure 11,12,13) [Nelson et al. 2002].  We also found that OPZ caused a 
significant increase in GSH levels and in GST activity in ρ0 cells, indicating that the 
pathway regulating the phase 2 enzyme response is preserved in cells lacking mtDNA. 
Interestingly, total GSH levels in control ρ0 cells were substantially lower than control ρ+  
cells and GSH Nernst redox potential showed that ρ0 cells were slightly more oxidized 
than ρ+  cells. The same finding has previously been reported for ρ0 143B osteosarcoma 
cells [Jiang et al. 1999, Vergani et al. 2004]. The reason for these differences are 
currently not clear. However, given that OPZ elicited a similar GSH response in both 
cells types, it is concluded that GSH synthesis is intact in CEM ρ0 cells.  
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Mitochondrial GSH is a critical antioxidant that protects cells from oxidative stress 
originating from the mitochondrial ETC or due to stimulation by exogenous factors 
[Armstrong et al. 2002]. Depletion of this small pool of GSH leads to loss of cell viability 
[Meredith and Reed 1982]. Therefore, it was important to determine the effect of OPZ on 
mitochondrial GSH concentrations. OPZ treatment of both CEM ρ+ and ρ0 cells 
significantly increased the mitochondrial GSH fraction, which is consistent with a 
previous report [Nelson et al. 2002]. The pattern of the increase of mitochondrial GSH 
was similar to that of total GSH. An explanation for this is that mitochondria do not 
synthesize their own GSH and they must transport GSH from the cytosol into their matrix 
via GSH transporters. Therefore the GSH level in mitochondria is a reflection of the 
concentration in the cytosol. 
 
In this study, it was found that GST activity was significantly increased and GSH level 
significantly decreased in the ρ0 cell line. It can be hypothesized that these observations 
may be due to the induction of the phase 2 enzyme response by EtBr used to create and 
maintain the ρ0 cells. As EtBr is a toxin, cells may use GSH in order to inactivate and 
eliminate the compound, resulting in reduced cellular GSH concentrations. The cells are 
also likely to respond to EtBr by raising the phase 2 enzyme response, leading to 
increased GST activity. Therefore, when studying the phase 2 enzyme induction system 






 4.3 Phase 2 enzyme response in CEM ρ0 cells is functional and protects against   
     DEM-induced GSH depletion 
     Our results indicated that OPZ induces a phase 2 response in both ρ+ and ρ0 cells. In 
order to determine whether this phase 2 response is functional to protect cells from 
eletrophile-induced oxidative stress, we exposed the cells to DEM, an electrophile which 
is known to deplete cellular GSH. It was found that OPZ protected both ρ+ and ρ0 cells 
partially from DEM-induced GSH depletion. The protective effect of OPZ was lower in 
mitochondria compared to whole cells, suggesting that the mitochondrial GSH pool is 
more susceptible to DEM-mediated GSH depletion. Furthermore, it was noted that the 
ability of OPZ to protect from DEM-dependent GSH depletion was reduced in ρ0 cells 
compared to the wild type cells. These results suggest that under conditions of increased 
stress the mitochondrial ETC may contribute to the OPZ-mediated phase 2 induction. 
It was furthermore determined whether OPZ pretreatment confers protection against 
DEM-induced mitochondrial and cellular damage in both ρ+ and ρ0 cells. DEM treatment 
of ρ+ and ρ0 cells induced a marked increase in cellular ROS (as measured using DCF 
fluorescence) which peaked at about 30 minutes after DEM addition. OPZ pretreatment 
was found to completely prevent this increase in cellular ROS in both cell types. Given 
that the ability of OPZ to maintain cellular GSH in the presence of DEM was relatively 
modest, it is likely that OPZ-dependent induction of other antioxidant enzymes (e.g. 
SOD, heme oxygenase-1) contributes to its protective effect. 
DEM treatment was found to induce mitochondrial ultrastructural changes, such as 
increased electron density of remodeled mitochondrial cristae, in CEM ρ+ cells. These  
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 changes may be a result of the increased ROS upon DEM treatment, which can lead to 
membrane damage via peroxidation of membrane lipids. OPZ conferred a remarkable 
protective effect on DEM-induced mitochondrial damage, suggesting that the OPZ 
induced phase 2 response is functional. 
 
4.4 Effects of OPZ on superoxide production 
     If mitochondrial ROS is not responsible for activation of Nrf2 by OPZ, then what 
could be the mechanism? 
Currently the exact mechanism of action of OPZ is unknown, but two mechanisms have 
been suggested [Velayutham et al. 2005a]. The first hypothesis proposes that OPZ acts as 
an electrophile and reacts directly with thiols in Keap1, leading to cysteine oxidation and 
formation of disulfide bridges. The second proposed mechanism involves the oxidation of 
Keap1 as a result of OPZ induced ROS. In support of the second hypothesis, it has 
recently been reported that OPZ can generate superoxide in the presence of oxygen, as 
measured by electron paramagnetic resonance (EPR) spin trapping [Velayutham et al. 
2005b]. OPZ-induced superoxide production was not affected significantly by addition of 
human embryonic kidney 293 (HEK293) cells. This result indicates that superoxide 
production is the consequence of the direct reaction of OPZ with oxygen and does not 
require the presence of cellular enzymes. This is also in agreement with our finding that a 
functional mitochondrial electron transport chain (ETC) is not necessary for OPZ-
induced ROS generation. A further report demonstrated that a major metabolite of OPZ 
in the presence of GSH produces superoxide which was detected by EPR spectroscopy  
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when the unstable free radical was trapped by 5,5-dimethyl-1-pyrroline-N-oxide (DMPO) 
to form a more stable  DMPO-OOH superoxide radical adduct (see Figure 20, which was 
taken from [Velayutham et al. 2005a]). Therefore these results suggest that the 
mechanism of action of OPZ involves both GSH and generation of superoxide. 
In line with this proposed mechanism, it was found in this study that OPZ treatment of 
cells leads to an increase in H2O2 and superoxide (as measured by DCF and DHE 
fluorescence, respectively), in both CEM ρ+ and ρ0 cells, thus confirming that 
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Figure 20. EPR spectra of superoxide radical adduct of DMPO formed from OPZ 
metabolite 4 and 5 and GSH in DMSO.  
(Reproduced with permission from Dr M.Velayutham, The Ohio State University College 
of Medicine: [Velayutham et al. 2005a]) 
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 4.5 Future Work 
     To confirm whether the proposed mechanism for OPZ induced phase 2 enzymes via 
superoxide is true, further investigations must be carried out (Figure 21). 
To investigate whether production of superoxide by OPZ to regulate the phase 2 enzyme 
response actually requires reduced form of glutathione (GSH) or simply a reducing agent, 
one can try to deplete GSH via treating the cells with buthionine sulfoximine (BSO) at a 
suitable concentration and duration. This can be followed by replacing the depleted GSH 
with another reducing agent e.g. dithiothreitol (DTT). A comparison of the superoxide 
production between both CEM ρ+ cells with and without BSO treatment before addition 
of OPZ can then be carried out. If the level of superoxide in CEM ρ+ cells is lower as 
compared to the untreated cells, this may indicate that GSH is required by the cells to 
produce superoxide.  
The next experiment to carry out is to deplete superoxide via addition of a suitable free 
radical scavenger (for instance using a synthetic SOD /catalase mimetic compound such 
as EUK-134) prior to OPZ treatment. If upregulation of GSH level and GST activity is 
not detected under these conditions, superoxide may be involved in the downstream 
activation of glutathione synthesizing enzymes and GST.  
To investigate whether upregulation of the GSH level and GST activity by OPZ is via 
activation of Nrf2, Nrf 2 protein in CEM ρ+ cells can be knocked down using small 
interfering RNA (siRNA) technology. Comparison of the GSH level and GST activity in 
wild type cells and cells without Nrf2 can then be carried out. If GSH level and GST 
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activity is reduced in Nrf2 silenced cells, Nrf2 is likely to be involved in the activation of 
glutathione synthesizing enzymes and GST. 
Finally, it will be interesting to investigate the influence of OPZ on other Nrf 2 controlled 
antioxidants or enzymes such as NAD(P)H:quinone oxidoreductase-1 and Heme-



















































     Figure 21.  Proposed mechanism for regulation of phase 2 enzyme response by     
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5.  CONCLUSIONS 
 
     In this study, the mechanism through which OPZ acts as a chemopreventive agent was 
investigated. OPZ is a representative of the dithiolethione class of phase 2 enzyme 
inducers, which exert their chemopreventive effects by promoting the detoxification of 
procarcinogenic xenobiotics as well as by enhancing the cellular oxidative defence. OPZ 
has shown promising results in trials when used as chemopreventive agent and was 
therefore chosen for this study with the aim to further elucidate its mechanism of action. 
 
     The study demonstrates that OPZ induced a phase 2 response in both ρ+and ρ0 cells CEM 
cells. Thus, OPZ treatment resulted in increased concentrations of reduced GSH levels (total 
and mitochondrial) and increased GST activity. Pretreatment with OPZ in both ρ+and ρ0 cells 
resulted in increased resistance to ROS production, loss of the mitochondrial membrane 
potential (Δψm) and cell death in response to the GSH depleting agent DEM. These effects 
are due to induction of the phase 2 enzyme response. The finding that the response is 
conserved in cells lacking mtDNA suggests a mitochondria-independent mechanism for the 
Nrf2-dependent activation of phase 2 enzymes by OPZ. 
     In view of the available data generated from this study and work done by other 
researchers, the following mechanism for regulation of the phase 2 enzyme response by 
OPZ is proposed. OPZ does not stimulate mitochondria to produce ROS to oxidize 
Keap1. Instead, a metabolite of OPZ might directly react with GSH to form superoxide in 
the cytosol [Velayutham et al. 2005a]. The superoxide will be converted to H2O2 in the 
presence of CuZnSOD.  The H2O2 then acts to oxidize cysteine residues in Keap1,  
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 resulting in the release of Nrf 2 from the complex and its translocation into the nucleus 
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Oltipraz, a member of a class of 1,2-dithiolethiones, is a potent phase 2 enzyme inducing agent 
used as a cancer chemopreventive. In this study, we investigated regulation of the phase 2 
enzyme response and protection against endogenous oxidative stress in lymphoblastic leukemic 
parental CEM cells and cells lacking mitochondrial DNA (mtDNA) (ρ0) by oltipraz. 
Glutathione (GSH) levels (total and mitochondrial) and glutathione S-transferase (GST) activity 
were significantly increased after pretreatment with oltipraz in both parental (ρ+) and ρ0 cells, 
and both cell lines were resistant to mitochondrial oxidation, loss of mitochondrial membrane 
potential and cell death in response to the GSH depleting agent diethylmaleate. These results 
show that the phase 2 enzyme response, by enhancing GSH-dependent systems involved in 
xenobiotic metabolism, blocks endogenous oxidative stress and cell death, and that this response 
is intact in cells lacking mtDNA.   
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Oltipraz, a member of a class of 1,2-dithiolethiones, is a potent phase 2 enzyme inducing agent used as a cancer chemopreventive. In
this study, we investigated regulation of the phase 2 enzyme response and protection against endogenous oxidative stress in lymphoblas-
tic leukemic parental CEM cells and cells lacking mitochondrial DNA (mtDNA) (q0) by oltipraz. Glutathione (GSH) levels (total and
mitochondrial) and glutathione S-transferase (GST) activity were signiﬁcantly increased after pretreatment with oltipraz in both parental
(q+) and q0 cells, and both cell lines were resistant to mitochondrial oxidation, loss of mitochondrial membrane potential, and cell death
in response to the GSH depleting agent diethylmaleate. These results show that the phase 2 enzyme response, by enhancing GSH-depen-
dent systems involved in xenobiotic metabolism, blocks endogenous oxidative stress and cell death, and that this response is intact in cells
lacking mtDNA.
 2005 Elsevier Inc. All rights reserved.
Keywords: Oltipraz; Glutathione; q0; mtDNA; Glutathione S-transferase; Mitochondrial permeability transition; Reactive oxygen species1,2-Dithiol-3-thiones are ﬁve-membered cyclic
sulfur-containing compounds with antioxidant, chemo-
therapeutic, and chemoprotective activities [1]. Oltipraz,
4-methyl-5-pyrazinyl-3H-1,2-dithiole-3-thione, is a com-
pound that has been shown to increase the activity of en-
zymes involved in the synthesis of glutathione (GSH),
and certain phase 2 detoxiﬁcation enzymes, including
glutathione-S-transferase (GST) [2–4]. While GSH or its
precursor amino acids have been shown to protect cells0006-291X/$ - see front matter  2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.bbrc.2005.09.059
q Abbreviations: GSH, glutathione; q0, rho 0; MMP, mitochondrial
membrane permeabilization; DEM, diethylmaleate; ANT, adenine nucle-
otide translocator; MPT, mitochondrial permeability transition; BgK,
bongkrekic acid; Nrf2, nuclear transcription factor erythroid 2p45 (NF-
E2)-related factor 2; Keap1, Kelch-like ECH-associated protein-1.
* Corresponding author. Fax: +65 6779 1453.
E-mail address: bchjsa@nus.edu.sg (J.S. Armstrong).against oxidant-induced cell death [5,6], GSH depletion
or cysteine starvation, which leads to GSH depletion,
has been shown to increase oxidative stress, induce the
mitochondrial permeability transition (MPT), and cause
cell death [7,8].
The factors involved in the regulation of mitochondri-
al integrity are complex and predominantly involve the
Bcl-2 family of proteins which regulate mitochondrial
outer membrane permeabilization [9,10] and GSH, which
regulates the redox state of mitochondrial protein vicinal
thiols involved in the mitochondrial permeability
transition (MPT) independently of Bcl-2 [7,11,12]. The
MPT is also regulated, in part, by the mitochondrial
respiratory chain (MRC) since pharmacological
inhibition of respiratory complex III (cytochrome bc1)
with stigmatellin and complex VI (adenine nucleotide
translocator) with bongkrekic acid both of which block
376 Y.L. Chua et al. / Biochemical and Biophysical Research Communications 337 (2005) 375–381oxidative phosphorylation (OX-PHOS) prevents or de-
lays the MPT and cell death after GSH depletion
[7,8,13].
In this study, we used a lymphoblastic leukemic CEM
cell line deﬁcient in mitochondrial DNA (mtDNA) and
the phase 2 inducing agent oltipraz to determine: (1)
whether enhancing GSH-dependent systems protected
against endogenous oxidative stress caused by the GSH
depleting agent diethylmaleate (DEM) and (2) whether this
response was conserved in cells lacking mtDNA. We found
that oltipraz pretreatment prevented reactive oxygen spe-
cies (ROS) formation, MPT, and cell death after GSH
depletion and that this eﬀect was conserved in cells lacking
mtDNA. These results suggest that oltipraz may be a useful
pharmacological strategy to prevent oxidative stress-in-
duced cell death caused by loss of GSH by enhancing
GSH-dependent systems involved in xenobiotic
metabolism.
Materials and methods
Chemicals and cell culture. All chemicals were of reagent grade and
were obtained from Sigma chemical company. DEM was used at 5 mM
for ROS assays, mitochondrial determinations, and cell viability studies.
Tetra-methyl rhodamine methyl ester (TMRM) and dichloroﬂuorescein
diacetate (DCFDA) were obtained from Molecular Probes (Eugene,
Oregon). CEM parental (q+) cells were cultured in RPMI, and 10% FBS
and supplements as described previously [13]. Cells were passaged daily to
maintain them in log-phase growth and kept at a nominal concentration of
2.5–5 · 105/ml. CEM q0 cells were derived from CEM cells by culturing in
the presence of 50 ng/ml of ethidium bromide for 4–6 weeks. These q0 cells
were then cultured in RPMI with 1 mM pyruvate and 50 lg/ml uridine,
and regularly monitored for KCN-sensitive oxygen consumption. Oltipraz
was obtained from LTK Laboratories (St. Paul, Minnesota) and cells were
pretreated with 50 lM oltipraz for 16.5 h prior to experimentation. Cell
viability was determined by trypan blue exclusion.
Biochemical methods. Oxygen consumption was determined polaro-
graphically using a Clarke-type oxygen electrode (Hansatech Instruments,
Norfolk, England); GSH and GSSG levels and GST activity were mea-
sured using commercial kits (Cayman Chemicals, Ann Harbor, MI, USA);
the GSH redox potential (Eh) was calculated using the Nernst equation
using a cell volume as 7 ll per million cells [14] and E0 at pH 7.0 was taken
as 240 mV [15]. Mitochondrial isolation was performed according to [16]
with modiﬁcation. Protein concentration of each fraction was determined
by the Dc protein assay (Bio-Rad, Hercules, CA).
Measurement of oxidation (ROS) production and mitochondrial
membrane potential (Dwm). Flow cytometry determinations for cellular
ROS formation and Dwm were performed as described previously [13].
Brieﬂy, for ROS determination, cells were treated with DEM for 0, 10,
20, 30, 40, 50, and 60 min, loaded with 10 lM DCFDA for 15 min,
washed with phosphate-buﬀered saline containing 10 mM glucose, and
analyzed immediately by ﬂow cytometry using the FITC channel (log
mode). In each analysis, 10,000 events were recorded. For determina-
tion of Dwm, cells were treated with DEM for 0, 30, 60, 90, 120, and
150 min, and loaded with 250 nM TMRM (TMRM is a cationic dye
which accumulates within mitochondria in accordance with the Dwm
Nernst potential) for 15 min and red ﬂuorescence was determined by
ﬂow cytometry using the PE channel [13]. The protonophore carbonyl-
CCCP (10 lM) was used to dissipate the chemiosmotic proton gradient
(DlH+) and served as a control for loss of Dwm. In each analysis,
10,000 events were recorded.
Electron microscopic examination of CEM cells. CEM cells in the
logarithmic proliferation phase were cultured with RPMI and DEM
(5 mM) ± oltipraz for 120 min and were ﬁxed with 2.5% glutaraldehyde in0.1 M cacodylate buﬀer, pH 7.4, at room temperature for 1 h. The cells
were prepared for electron microscopic (EM) as described previously [13].
Brieﬂy, cells were washed with 0.1 M cacodylate buﬀer and post-ﬁxed with
1% osmium tetraoxide in 0.1 M cacodylate buﬀer. Finally, the cells were
dehydrated with graded series of ethanol and embedded in LX112. Thin
sections were prepared and stained with uranyl acetate. Specimens were
examined on a JEOL 1000X electron microscope operating at 80 kV.
Statistical analysis. Statistical analyses were performed using one-way
ANOVA and p values <0.05 were considered signiﬁcant. Data are pre-
sented as means ± SEM.Results
GSH levels are increased in CEM q+ and q0 cells after
treatment with oltipraz
GSH and GSSG levels and GSH redox (Eh) potential
were determined on aliquots of CEM q+ and q0 cells pre-
treated with oltipraz ± DEM. Oltipraz pretreatment in-
creased GSH levels in q+ cells from 60.8 ± 4.2 nmol/mg
protein to 85.4 ± 5.9 nmol/mg protein (P < 0.05) and in-
creased GSH levels in q0 cell from 38.9 ± 2.2 nmol/mg pro-
tein to 64.7 ± 5.2 nmol/mg protein (P < 0.05) (Fig. 1A).
This represents an approximate 40% increase in GSH levels
in q+ cells and an approximate 60% increase in GSH in q0
cells. DEM treatment for 2 h signiﬁcantly reduced GSH
levels (>95%) in both q+ (0.24 ± 0.07 nmol/mg protein)
and q0 (0.47 ± 0.07 nmol/mg protein) cell lines. Pretreat-
ment of cells with oltipraz prevented GSH depletion after
DEM treatment since GSH levels were 15.9 ± 1.2 nmol/
mg protein in q+ cells and 6.3 ± 1.0 nmol/mg protein in
q0 cells.
Oltipraz pretreatment increased mitochondrial GSH lev-
els in q+ cells from 6.2 ± 0.3 nmol/mg protein to
7.6 ± 0.5 nmol/mg protein (P < 0.05) and increased mito-
chondrialGSH levels inq0 cells from4.3 ± 0.5 nmol/mgpro-
tein to 5.1 ± 0.2 nmol/mg protein (P < 0.05) (Fig. 1B). This
represents an approximate 20% increase in mitochondrial
GSH levels in both q+ and q0 cells. DEM treatment for 2 h
signiﬁcantly reduced mitochondrial (>95%) in both q+
(0.31 ± 0.04 nmol/mg protein) and q0 (0.26 ± 0.02 nmol/
mg protein) cell lines. Pretreatment of cells with oltipraz pre-
vented mitochondrial GSH depletion after DEM treatment
since mitochondrial GSH levels were 1.156 ± 0.5 nmol/mg
protein in q+ cells and 0.389 ± 0.1 nmol/mg protein in q0
cells.
The GSH Nernst redox potential (Eh) increased
120 mV in q+ cells treated with DEM compared to
control cells and 30 mV in q+ cells pretreated with
oltipraz + DEM compared to control cells.
Eh = 264.3 ± 13.6 mV in control cells compared with
Eh = 138.5 ± 5.1 mV in DEM treated cells and
Eh = 287.6 ± 12.1 mV in q+ control cells treated with
oltipraz compared with 234.6 ± 11.1 mV in q+ cells treat-
ed with oltipraz + DEM (Table 1).
The GSH Nernst redox potential (Eh) increased 90 mV
in q0 cells treated with DEM compared to control cells and










































Fig. 1. (A) CEM parental q+ and q0 cells were incubated in RPMI ± 50 lM oltipraz for 16.5 h. GSH levels were determined on these samples as described
under Materials and methods. The GSH concentration is plotted as nanomole per milligram protein. Data are expressed as means ± SEM (n = 3). (B)
CEM parental q+ and q0 cells were incubated in RPMI ± 50 lM oltipraz for 16.5 h. Mitochondrial fractions were isolated as described under Materials
and methods. GSH levels were determined on these samples as described under Materials and methods. The GSH concentration is plotted as nanomole per
milligram protein. Data are expressed as means ± SEM (n = 3). (*P < 0.05).
Table 1
Aliquots of CEM parental q+ and q0 cells approximately 4 · 106/ml)
preincubated in RPMI ± 50 lM oltipraz for 16.5 h and then treated with
DEM or RPMI (control) for 0, or 120 min
Nernst GSH redox potential Eh (mV) q
+ q0
Control 264.3 ± 13.6 246.6 ± 12.7
DEM 138.5 ± 5.1 155.7 ± 10.1
Oltipraz 287.6 ± 12.1 272.4 ± 10.1
Olipraz + DEM 234.6 ± 11.1 202.8 ± 8.8
GSH and GSSG concentrations were determined by assays described
under Materials and methods. The GSH redox potential (Eh) in millivolt
was calculated using the Nernst equation as described under Materials and
methods. Data are expressed as means ± SEM (n = 3).
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compared with Eh = 155.7 ± 10.1 mV in DEM treated
q0 cells and Eh = 272.4 ± 10.1 mV in q0 control cells
treated with oltipraz compared with 202.8 ± 8.8 mV in
q0 cells treated with oltipraz + DEM (Table 1).
GST levels are increased in CEM q+ and q0 cells after
treatment with oltipraz
Oltipraz is known to increase the expression of phase 2
detoxiﬁcation enzymes. GST activity increased from
9.4 ± 0.6 to 14.9 ± 0.3 nmol/min/mg protein in q+ cells
treated with oltipraz for 16.5 h (P < 0.05). This representsan approximate 60% increase in GST activity. GST activity
increased from 13.5 ± 0.2 nmol/min/mg protein in q0 cells
to 18.6 ± 0.2 nmol/min/mg protein in CEM q0 cells after
treatment with oltipraz for 16.5 h (approximately 40%)
(P < 0.05) (Fig. 2).
GSH depletion causes oxidation (ROS) production in
CEM q+ and q0 cells which is blocked by pretreatment
with oltipraz
Cellular oxidation and ROS production were determined
in cells by monitoring the ﬂuorescence of the ROS-sensitive
dye DCF. Increased DCF ﬂuorescence, a measure of intra-
cellular oxidation and ROS production [7], was determined
by a shift in DCF ﬂuorescence to the right on the x-axis of
the FACS histogram. CEM parental q+ and q0 cells were
incubated inRPMI ± oltipraz. Fig. 3A shows representative
DCF FACS histograms of CEM cells stained with DCFDA
and analyzed using FITC channel as described in the meth-
ods section. Aliquots of q+ and q0 cells (2 · 106/ml) were
treated with DEM for 0, 10, 20, 30, 40, 50, and 60 min,
washed inPBS, and suspended inPBScontaining10 mMglu-
cose. Cells were loaded with 10 lMDCFDA for 15 min and
ﬂuorescencewasmeasuredbyﬂowcytometryusing theFITC
channel. Fig. 3Ashows thatDEMtreatment caused theDCF
ﬂuorescence to shift right on the x-axis of the FACS histo-























Fig. 2. CEM parental q+ and q0 cells were incubated in RPMI ± 50 lM
oltipraz for 16.5 h and GST activity was determined as described under
Materials and methods. GST activity in parental CEM q+ cells was
9.4 ± 0.6 nmol/min/mg protein compared to 14.9 ± 0.3 nmol/min/mg
protein after treatment with oltipraz. GST activity of CEM q0 cells was
13.5 ± 0.2 nmol/min/mg protein compared to 18.6 ± 0.2 nmol/min/mg
protein after treatment with oltipraz. (*P < 0.05).
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mean DCF ﬂuorescence (a.u.) of CEM parental q+ and q0
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Fig. 3. (A) CEM parental q+ and q0 cells were incubated in RPMI ± 50 lM o
CEM cells stained with DCFDA and analyzed using FITC channel as describ
were treated with DEM for 0, 10, 20, 30, 40, 50, and 60 min, washed in PBS,
10 lM DCFDA for 15 min and ﬂuorescence was measured by ﬂow cytometry
experiments. In each analysis, 10,000 events were recorded. (B) Bar graph s
determined from mean ﬂuorescence (a.u.) of FACS histograms as described ab
means ± SEM (n = 3). (C) Top panel shows representative FACS histogram
treatment with 50 lM oltipraz for 16.5 h. Bottom panel shows bar graph of m
after treatment with 50 lM oltipraz for 16.5 h. Data are expressed as means ±mined frommean ﬂuorescence (a.u.) of FACS histograms as
described above. In each analysis, 10,000 events were record-
ed.Data are expressed asmeans ± SEM(n = 3).Fig. 3C (top
panel) shows a representative DCF FACS histogram of
CEM cells stained with DCFDA and analyzed using FITC
channel as described in the methods section before and after
treatment with oltipraz. Figure shows that oltipraz increased
the basal DCF ﬂuorescence in both parental q+ and q0 cells.
Fig. 3C (bottompanel) shows abar graphofmeanDCFﬂuo-
rescence (a.u.) of CEM parental q+ and q0 cells. The basal
DCF ﬂuorescence increased from 80.3 ± 4.2 (a.u.) to
125.3 ± 14.8 (a.u.) in q+ cells treated with oltipraz
(P < 0.05). The basal DCF ﬂuorescence increased from
138.0 ± 10.3 (a.u.) in q0 cells to 205.8 ± 14.1 (a.u.) in CEM
q0 cells after treatment with oltipraz (P < 0.05).
GSH depletion causes ultrastructural changes in
mitochondrial cristae of CEM cells and loss of Dwm that is
blocked by pretreatment with oltipraz
Fig. 4A, caption ‘‘1’’ shows typical mitochondrial struc-

























ltipraz for 16.5 h. Figure shows representative DCF FACS histograms of
ed under Materials and methods. Aliquots of q+ and q0 cells (2 · 106/ml)
and suspended in PBS containing 10 mM glucose. Cells were loaded with
using the FITC channel. Representative example from three independent
howing mean DCF ﬂuorescence (a.u.) of CEM parental q+ and q0 cells
ove. In each analysis, 10,000 events were recorded. Data are expressed as
s of CEM parental q+ and q0 cell of DCF ﬂuorescence before and after
ean DCF ﬂuorescence (a.u.) of CEM parental q+ and q0 cells before and















Fig. 4. (A) Representative electron micrographs (EM) of CEM cells incubated in RPMI ± 50 lM oltipraz for 16.5 h and then treated with DEM or RPMI
(control) for 0, or 120 min. Fig. 2A, caption 1 shows mitochondria in control cells; inset arrowheads point to mitochondrial cristae. Caption 2 shows
mitochondria of cells treated with DEM; inset arrowheads point to: (a) fragmented electron dense mitochondrion, (b) mitochondrion showing increased
electron density of mitochondrial cristae, and (c) vacuolated mitochondrion. Caption 3 shows mitochondria of cells treated with DEM + oltipraz; inset
arrowheads point to mitochondrial cristae. EM results suggest that oltipraz preserves mitochondrial cristae (the sites of electron transport and oxidative
phosphorylation) after GSH depletion compared to DEM treatment alone in which the mitochondria ultrastructure is signiﬁcantly altered. (B)
Representative ﬂow cytometric analysis of CEM cells stained with TMRM and analyzed using PE channel as described under Materials and methods.
CEM parental q+ and q0 cells were incubated in RPMI ± 50 lM oltipraz for 16.5 h. Figure shows representative FACS histograms of CEM cells loaded
with TMRM and analyzed using PE channel as described under Materials and methods. Aliquots of q+ and q0 cells (2 · 106/ml) were treated with DEM
for 0, 30, 60, 90, 120, and 150 min, washed in PBS, and suspended in PBS containing 10 mM glucose. Cells were loaded with 250 nM TMRM for 15 min
and red ﬂuorescence was measured by ﬂow cytometry using the PE setting. Representative example from at least three independent experiments. In each
analysis, 10,000 events were recorded.
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ultrastructure of CEM cell mitochondria. Caption ‘‘2’’
shows mitochondria of cells treated with DEM; inset
arrowheads point to: (a) small fragmented electron dense
mitochondrion, (b) mitochondrion showing increased elec-
tron density of remodeled mitochondrial cristae, and (c)
typical vacuolated mitochondrion. Caption ‘‘3’’ shows
mitochondria of cells pretreated with 50 lM oltipraz for
16.5 h and then treated with DEM for 120 min; inset
arrowheads point to mitochondrial cristae. EM results
indicate that oltipraz pretreatment preserved mitochondri-
al ultrastructure after GSH depletion. Fig. 4B shows the
Dwm of q
+ and q0 cells (determined by monitoring the ﬂuo-
rescence of cells loaded with the membrane potential dye
TMRM). Decreased TMRM ﬂuorescence, a measure of
cells with decreased Dwm, was determined by a shift in
TMRM ﬂuorescence to the left on the x-axis of the FACS
histogram. Fig. 4B shows that cells with decreased TMRM
ﬂuorescence signiﬁcantly increased in number approxi-mately 90 min after treatment with DEM and this was
blocked by pretreatment with oltipraz in both q+ and q0
cell lines.
Oltipraz blocks cell death in CEM q+ and q0 cells after
GSH depletion
Since oltipraz blocked ROS production and preserved
mitochondrial structure and Dwm of CEM cells, we
determined cell viability after DEM treatment. Fig. 5
shows that oltipraz pretreatment signiﬁcantly preserved
cell viability in q+ and q0 cells after treatment with
DEM.
Discussion
The phase 2 enzyme induction system is crucial for
detoxiﬁcation of carcinogens by conjugation with GSH
which increases their solubility and allows their excretion

















Fig. 5. CEM cells were incubated in RPMI ± 50 lM oltipraz for 16.5 h.
Aliquots of cells were treated with either RPMI (control) or DEM for
10 h. Cell viability was determined at 1 h intervals during the time course
of the experiment. Control omitted for clarity. Cell viability was
determined by trypan blue analysis. Data are expressed as means ± SEM
(n = 3).
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in aging [20], has any eﬀect on this important detoxiﬁcation
system; however, decline in the eﬃcacy of this system
would predispose cells to increased carcinogen overload
and cell transformation. Our present results show that
oltipraz induces the phase 2 enzyme response in both q+
and q0 cells with similar eﬃcacy and this system protects
cells against endogenous oxidative stress mediated by
GSH depletion.
In agreement with previous reports we found that oltip-
raz signiﬁcantly increased GSH levels and GST activity [5];
however, we also found that oltipraz caused a signiﬁcant
increase in GSH levels and in GST activity in q0 cells, indi-
cating that the pathway regulating the phase 2 response is
conserved in cells lacking mtDNA. Interestingly, total
GSH levels were lower in control q0 cells compared to con-
trol q+ cells and GSH Nernst redox potential showed that
q0 cells were more oxidized than q+ cells which has previ-
ously been reported in q0 osteosarcoma cells [21]. While,
on the other hand, GST activity was signiﬁcantly increased
in the q0 cell line which may be the result of the ethidium
bromide used to create the cell line inducing a phase 2 en-
zyme response. Mitochondrial GSH is a critical factor in
protecting cells from oxidative stress and oltipraz treat-
ment signiﬁcantly increased mitochondrial GSH, as previ-
ously reported [5], suggesting that protection against
DEM-mediated toxicity may be due, in part, to the in-
creased mitochondrial GSH fraction [22,23]. On the other
hand, since the phase 2 response also protects against oxi-
dative stress by increasing cellular antioxidants including
manganese superoxide dismutase (MnSOD) and heme oxy-genase-1 (HO-1) [24,25] suggests that a multiplicity of fac-
tors may be involved in the phase 2 response especially
since cells lacking mtDNA are known to have increased
levels of HO-1 and MnSOD [26].
Protection against DEM-mediated toxicity by pretreat-
ment of cells with oltipraz appears to be the result of in-
creased phase 2 detoxiﬁcation potential (including GSH
levels and GST activity) since after oltipraz treatment
DEM did not completely deplete cellular GSH and the
GSH Nernst redox potential of cells was signiﬁcantly more
reduced compared to DEM treatment alone (Table 1).
Since it is known that GSH regulates the redox status of
mitochondrial protein vicinal thiols involved in regulation
of the MPT [7,11,12], it is likely that the preservation of cel-
lular and mitochondrial GSH levels by oltipraz was
responsible for blocking the activation of the MPT and cell
death.
The major metabolite of oltipraz, a pyrrolopyrazine thi-
one, has been shown to be a phase two enzyme inducer via
the formation of a GSH stimulated redox cycle producing
superoxide radical suggesting a possible mechanism by
which oltipraz might increase in the transcription of phase
2 enzymes mediated by nuclear transcription factor ery-
throid 2p45 (NF-E2)-related factor 2 (Nrf2) [27]. The pyr-
rolopyrazine thione-dependent production of superoxide
anion could cause redox-dependent dissociation of Nrf2
from Keap1, allowing it to translocate to the nucleus and
activate its antioxidant response element (ARE), causing
transcriptional regulation of target genes. In keeping with
this idea, we found that oltipraz treatment increased basal
DCF ﬂuorescence in both cell lines (indicating increased
oxidative stress) compared to untreated control cells
(Fig. 3C). Our results, therefore, indicate that this redox
mechanism of Nrf2 activation is independent of a function-
al respiratory chain and therefore of mitochondrial ROS
production.
In summary, our data show that oltipraz protected
cells against endogenous oxidative stress caused by
GSH depletion, mitochondrial permeability transition,
and cell death by inducing the phase 2 response and that
this is conserved in cells lacking mtDNA indicating that
the Nrf2-ARE core signaling pathway is intact in the ab-
sence of a functional MRC. Oltipraz, which is already in
use in phase 2 clinical trials is rapidly adsorbed and is
therefore ideally suited for oral use [28], may provide
an alternative approach for the design and development
of potential therapeutic antioxidants in age-related dis-
eases where there is oxidative stress component, especial-
ly since progressive loss of mtDNA is characteristic
feature of aging.
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